01—Abstract
Summary
Summary of the 10-K filed March 26, 2014. Cited figures are marked; the original filing is the authoritative source.
Zoetis Inc. (ZTS) has filed its 2013 Annual Report on Form 10-K, detailing its performance and strategic positioning as a newly independent entity following its separation from Pfizer Inc. The company is a global leader in animal health, focusing on the discovery, development, manufacture, and commercialization of medicines and vaccines for both livestock and companion animals.
In 2013, Zoetis reported total revenue of $4.56 billiona, a 5% increase driven by operational growth across all segments, despite a 2% unfavorable impact from foreign exchange. The U.S. segment remains the largest contributor to revenue at 42%. The company emphasizes its strong R&D capabilities, with a focus on product lifecycle development, and its extensive sales and marketing infrastructure, which allows for deep customer relationships.
Key product lines like ceftiofur, Revolution, and Draxxin contribute significantly to revenue. The report also highlights the company's financial restructuring, including a $3.65 billionb senior notes offering, and outlines strategies for future growth centered on emerging markets, innovation, and customer engagement.
02—Key points
Key Highlights
- Zoetis reported total revenue of $4.56 billion for 2013, a 5% increase over 2012, driven by operational growth and partially offset by unfavorable foreign exchange impacts.
- The company completed its separation from Pfizer Inc. in 2013, marking its first full year as an independent public company, including an IPO and a $3.65 billion senior notes offering.
- Revenue is diversified across four geographic segments: U.S. (42%), Europe/Africa/Middle East (25%), Canada/Latin America (17%), and Asia/Pacific (16%).
- Livestock products accounted for 64% of revenue, while companion animal products made up 36%, reflecting the company's balanced market approach.
- Research and Development (R&D) expenses were $399 million in 2013, with a strategic focus on product lifecycle development to enhance existing product lines.
- The company's top ten product lines contributed 39% of revenue, indicating a diversified revenue stream rather than over-reliance on a single product.
- Zoetis maintains a strong competitive position, leveraging its direct sales force and technical expertise to build strong customer relationships within the animal health industry.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2013filed March 26, 2014Financial Statements
FY2013 against FY2012
| Line item | FY2013FY2012 | Change |
|---|---|---|
| Revenue | $4.56B$4.34B | +5.2% |
| Cost of Revenue | $1.67B$1.56B | +6.8% |
| Gross Profit | $2.89B$2.77B | +4.3% |
| SG&A Expenses | $1.61B$1.47B | +9.7% |
| Interest Expense | $113.00M$31.00M | +264.5% |
| Net Income | $503.00M$436.00M | +15.4% |
| EPS (Basic) | $1.01$0.87 | +16.1% |
| EPS (Diluted) | $1.01$0.87 | +16.1% |
| Shares Outstanding (Basic) | 500.00M500.00M | 0.0% |
| Shares Outstanding (Diluted) | 500.32M500.00M | +0.1% |
05—Questions
Frequently Asked Questions
What was Zoetis's primary financial performance in 2013?
In 2013, Zoetis reported total revenue of $4.56 billion, an increase of 5% compared to 2012, driven by strong operational growth across its segments. Net income attributable to Zoetis was $504 million. The company benefited from an IPO and a senior notes offering, marking its first year as an independent public company.
How does Zoetis's revenue break down by product type and geography?
Zoetis's revenue is derived from both livestock (64%) and companion animal (36%) products. Geographically, the United States is the largest segment (42%), followed by Europe/Africa/Middle East (25%), Canada/Latin America (17%), and Asia/Pacific (16%).
What are Zoetis's key growth strategies and R&D focus?
Zoetis's growth strategies include leveraging its direct local presence and customer relationships, further penetrating emerging markets, pursuing new product R&D and lifecycle development, and expanding into complementary businesses like diagnostics and e-learning. The company's R&D efforts are primarily focused on product lifecycle development, aiming to enhance existing offerings.
What were the significant events in 2013 for Zoetis's corporate structure?
The most significant corporate event was the full separation from Pfizer Inc. through an exchange offer completed in June 2013, establishing Zoetis as an independent public company. This also included a $3.65 billion senior notes offering and the commencement of trading on the NYSE in February 2013.
06—Continue